Metamizol Al

Metamizole sodium, the active ingredient in Metamizol Al, is a pyrazolone presented as an oral tablet for oral administration. It provides analgesic and antipyretic effects for the relief of pain and reduction of fever in adult patients.

GNH USA supplies Metamizol Al as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance for the European market. The company provides reliable logistics, documentation support, and responsive customer service to meet the needs of global healthcare providers.

Metamizol Al, a pyrazolone analgesic, acts on prostaglandin‑mediated pathways to relieve pain and fever.

Acute pain: provides rapid analgesic relief for sudden onset pain. Postoperative pain: reduces discomfort following surgical procedures. Fever: lowers elevated body temperature in febrile conditions. Cancer‑related pain: helps manage moderate pain associated with malignancy. Musculoskeletal pain: alleviates pain from injuries or inflammation. Dental pain: eases pain after dental procedures.

Metamizol Al can be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Dizziness - Hypotension

Serious or Rare Side Effects: - Agranulocytosis (severe reduction in white blood cells) - Severe skin reactions such as Stevens‑Johnson syndrome - Anaphylactic shock

When prescribing Metamizol Al, clinicians should consider several safety measures.

Assess renal function: evaluate before initiating therapy in patients with kidney disease. Monitor blood counts: perform regular complete blood count to detect agranulocytosis. Avoid in known hypersensitivity: discontinue if allergic reaction occurs. Use with caution in pregnancy: limited safety data, consider alternatives. Limit concurrent NSAIDs: increased risk of adverse effects. Store at room temperature: keep in original packaging, protect from moisture.

Metamizol Al may interact with other medicines, requiring careful assessment.

Major Interactions (Avoid): - Concurrent use with other pyrazolones: additive toxicity risk. - Co‑administration with anticoagulants: heightened bleeding potential. - Combination with methotrexate: enhanced myelosuppression.

Moderate Interactions (Monitor Closely): - CYP450 inhibitors: may increase plasma concentration of Metamizol. - Diuretics: may exacerbate hypotensive effects. - Allopurinol: possible increased risk of skin reactions.